Working In Oncology

Healthcare professionals tend to be hesitant about putting their views on the web. But not Dr. David Aboulafia [https://www.virginiamason.org/david-m-aboulafia-md] , Hematologist at Virginia Mason [https://www.virginiamason.org/] and author at Covid Cogitations [https://covidcogitations.wordpress.com/], who shares with us his best insights for developing a bedside manner online. Join us as we discuss: - Dr. Aboulafia’s generational heritage of healthcare - Origin and lessons of Covid Cogitations - How COVID-19 has affected cancer care and healthcare access - Artificial intelligence and genetic sequences: the future of cancer care? - The role of specialty pharmacies in partnering with staff and patients Check out these resources we mentioned during the podcast: - Dr. Aboulafia’s Covid Cogitations [https://covidcogitations.wordpress.com/] blog To hear more interviews like this one, subscribe to the Working In Oncology [https://blog.bioplusrx.com/oncology-podcast] Podcast on Apple Podcasts [https://podcasts.apple.com/us/podcast/working-in-oncology/id1534327783], Spotify [https://open.spotify.com/show/4URKTnxc0b0svVsw6mjnpo?si=DNrwAb8BSJKDKgphRh4ljQ&nd=1], or your preferred podcast platform.

In the midst of a pandemic, many patients are finding themselves making difficult choices: Should I go to my biopsy follow-up and risk catching COVID? Unfortunately, many patients feel the risk isn’t worth it to visit a medical facility. But this is creating huge implications when it comes to diagnosing and treating high-mortality diseases like liver and pancreatic cancer. Dr. Joshua Shaw [https://www.linkedin.com/in/joshua-shaw-09a579138/], Transplant Surgeon & HPB Surgical Oncologist at Broward Health [https://www.linkedin.com/company/broward-health/], joins the show to discuss his experiences, including ways to avoid delays in surgery, encouragement for those still avoiding in-person appointments, and new developments in surgical oncology. Here are the show highlights: - Patient tips & best practices to prevent delays in treatment (2:41) - The evolving definition of operability & what it means for cancer patients (6:16) - How COVID-19 has delayed treatment for cancer patients (13:27) - What to say to patients who are afraid to come in because of COVID (17:16) - How Dr. Shaw deals with stressful situations (23:50) Check out these resources we mentioned during the podcast: - J1shaw@browardhealth.org [J1shaw@browardhealth.org] - https://www.browardhealth.org/services/transplant-services [https://www.browardhealth.org/services/transplant-services] To hear more interviews like this one, subscribe to the Working In Oncology [https://blog.bioplusrx.com/oncology-podcast] Podcast on Apple Podcasts [https://podcasts.apple.com/us/podcast/working-in-oncology/id1534327783], Spotify [https://open.spotify.com/show/4URKTnxc0b0svVsw6mjnpo?si=DNrwAb8BSJKDKgphRh4ljQ&nd=1], or your preferred podcast platform.

Unmet need is a huge driver in the development of oncology treatments. But when it comes to choosing the therapies that “make the cut,” it’s not that simple. What are the risks involved? Where has efficacy been demonstrated in the treatment area and type? And the timeless question: who’s paying for it? Jeff Bockman [https://www.linkedin.com/in/jeffbockmancellohealth/], Ph.D. EVP & Oncology Practice Head at Cello Health BioConsulting [https://www.linkedin.com/company/cello-health/], joins us to share his experience and break down the criteria and considerations of how therapies are chosen and developed. Here are the show highlights: - Who are the players and decision-makers developing therapies? (3:18) - How developers decide which therapies to pursue (15:34) - How the element of risk complicates the goal of pursuing unmet needs (28:20) - Pipeline activity, precision oncology, and more trends in biotech (34:24) - Why we’ll see more “engineering of biology” in the next 5-10 years (39:28) Check out these resources mentioned during the podcast: Dr. Bockman’s LinkedIn [https://www.linkedin.com/in/jeffbockmancellohealth/] Dr. Bockman’s Email [jbockman@definedhealth.com] Cello Health’s Website [https://cellohealthbioconsulting.com/] To hear more interviews like this one, subscribe to the Working In Oncology [https://blog.bioplusrx.com/oncology-podcast] Podcast on Apple Podcasts [https://podcasts.apple.com/us/podcast/working-in-oncology/id1534327783], Spotify [https://open.spotify.com/show/4URKTnxc0b0svVsw6mjnpo?si=DNrwAb8BSJKDKgphRh4ljQ&nd=1], or your preferred podcast platform.

Everyone in the healthcare sector has heard of (and likely works toward) a patient-centric model. But what does it really mean? And how does it look in practice? Sherin Al-Safadi [https://www.linkedin.com/in/sherin-alsafadi/],, MSc, MBA, PhD Director of Global Medical Affairs Oncology at Bayer Pharmaceuticals [https://www.linkedin.com/company/bayer-pharmaceuticals/], joins the show to discuss her experience and insights on Bayer’s global mission to provide access for patients. We discuss the best practices and strategies used around the world to make sure the voice of the patient is kept at the highest volume — from the role of allied health professionals and caretakers to the evolving use of digital communication tools like telemedicine, text messages, and social media. Here are the show highlights: - The critical ecosystem of allied health professionals (3:16) - The 3 “buckets” of care inequalities she’s seen across different nations (8:52) - Best practices abroad that could be implemented in the U.S. (15:58) - Developments, improvements, and opportunities in telemedicine (20:43) - Text message, social media, and the evolving world of patient communication (26:21) To hear more interviews like this one, subscribe to the Working In Oncology [https://blog.bioplusrx.com/oncology-podcast] Podcast on Apple Podcasts [https://podcasts.apple.com/us/podcast/working-in-oncology/id1534327783], Spotify [https://open.spotify.com/show/4URKTnxc0b0svVsw6mjnpo?si=DNrwAb8BSJKDKgphRh4ljQ&nd=1], or your preferred podcast platform.

For patients who have run out of approved treatment options, hopes of fighting disease can feel diminished. Fortunately, through existing and new programs, patients have access to alternative drugs. Educating physicians more on the program availability can lead to an increase in options for patients and a more positive outlook to recovery. Dr. Ajeet Gajra [https://www.linkedin.com/in/ajeet-gajra-md-mbbs-facp-77059748/], Chief Medical Officer at Cardinal Health [https://www.linkedin.com/company/cardinal-health/] Specialty Solutions, joins the show to discuss experimental oncology drug use through the Expanded Access Program & the Right To Try Law. Here are the show highlights: - Expanded Access Program vs. The Right To Try Law - Hesitancy & Barriers to Use Programs - First Steps & How To Stay Up-To-Date on Programs - Tips for Office Staff w/ These Programs - Success & Future Use of Drugs Check out these resources we mentioned during the podcast: - Dr. Gajra’s LinkedIn (https://www.linkedin.com/in/ajeet-gajra-md-mbbs-facp-77059748/ [https://www.linkedin.com/in/ajeet-gajra-md-mbbs-facp-77059748/] - Dr. Gajra’s Research (https://ascopubs.org/doi/full/10.1200/OP.20.00569 [https://ascopubs.org/doi/full/10.1200/OP.20.00569]) - Cardinal Health (https://www.cardinalhealth.com/en.html [https://www.cardinalhealth.com/en.html]) To hear more interviews like this one, subscribe to the Working In Oncology [https://blog.bioplusrx.com/oncology-podcast] Podcast on Apple Podcasts [https://podcasts.apple.com/us/podcast/working-in-oncology/id1534327783], Spotify [https://open.spotify.com/show/4URKTnxc0b0svVsw6mjnpo?si=DNrwAb8BSJKDKgphRh4ljQ&nd=1], or your preferred podcast platform.